News
Yuhan Corporation to create a state-of-the-art R&D cluster in Gunpo-City, South Korea
Yuhan Corporation is working together with Gunpo City, South Korea to create a high-tech bio research base and CMC center in the industrial area of
Yuhan Corporation’s licensed-out non-alcoholic steatohepatitis drug to start phase 1 clinical trial in Europe
Expected to receive 10 million USD as a milestone payment Yuhan Corporation (000100. KS) announced on the 17th of November that the new drug candidate
Yuhan Corporation to invest 1.6 billion Won (1.34 million USD) in Yuhan USA U.S. Open Innovation Investment Continues
Yuhan USA strengthens its role as a ‘venture capital’. They purchased 750,000 shares of Processa Pharmaceuticals this year. Yuhan Corporation is spurring overseas open innovation expansion and strengthening
Processa Pharmaceuticals’ PCS12852, originally developed by Yuhan Corp, cleared by FDA to Proceed with Ph2a Trial for Gastroparesis
Processa Pharmaceuticals announced that they have been cleared by the FDA to proceed with a Phase 2a clinical trial of PCS12852 in patients with moderate
[Job Opening] Associate, Business Operations – San Diego office
Job description Responsibilities: Provide administrative support to include arranging travel plans and meetings; interact and liaise with members of the functional team, management and external
Yuhan Corporation – Introduction Video
Learn more about our parent company “Yuhan Corporation by watching this video.